Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
Authors' conclusion
Our results showed that GLP-1RA AOMs were not associated with an increased risk of AEs compared to non-GLP-1RA AOMs in patients who had previously undergone bariatric surgery. Prospective studies are needed to identify the optimal timeframe for GLP-1RA initiation.
Study context
- Population
- Patients aged 16–65 years after laparoscopic RYGB or SG who initiated antiobesity medications (AOMs); 83% female, median (IQR) age 47.8 (40.9–55.4) years
- Participants
- 599 patients
- Exposure
- GLP-1RA AOMs vs non-GLP-1RA AOMs after bariatric surgery
- Outcome
- AE incidence
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Adjusted odds ratio (95% CI)
GLP-1RAvs FDA-approved
1.1(0.5–2.6)
GLP-1RAvs Off-label
1.1(0.6–2.3)
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | P value |
|---|---|---|
| AEs by timing of AOM initiation: ≥12 vs <12 months after surgeryLower risk of AEs with ≥12 months | 0.01 (0.0–0.01) | P < 0.001 |
Original publication
Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery. Diabetes Obes Metab. Published 27 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →